BCL2 and melanoma: Additionally, due to gamma-secretase and B-cell lymphoma 2 (Bcl-2) expression of melanoma CSCs, correlated with that of ALDH, the administration of their inhibitors, i.e., gamma-secretase inhibitors (GSI) and myeloid cell leukaemia sequence 1 (MCL-1)—an inhibitor of Bcl-2—is targeting CSCs [231,232].